Liza Porteus Viana

Liza Porteus Viana

Governments, Financial Stakeholders Meet On Policy For IP As Collateral

By Liza Porteus Viana for Intellectual Property Watch
Intellectual property and financial stakeholders, representatives from developing and developed countries, and non-governmental organisations are in Vienna this week to work on a global guide on how to use intellectual property as collateral in commerce.

Intellectual Property And Access Can Co-Exist, US Rightsholders Say

By Liza Porteus Viana for Intellectual Property Watch WASHINGTON, DC – There is a growing backlash against intellectual property rights and international rules aimed at protecting innovation and ideas in certain parts of the globe, several pharmaceutical and other innovator…

Economic Crisis Sends IP Owners (And Their Lawyers) Looking For Protection

By Liza Porteus Viana for Intellectual Property Watch
NEW YORK - As the value of intellectual property increases in the innovation economy, an increasing number of IP owners are trying to guard their ideas and innovations through business-method patents, international trade agreements, biological patents and other forms of protection.

But amid the economic crisis roiling the financial markets around the world and trickling down to Main Street, intellectual property owners often need to weigh the costs and benefits of protecting their IP assets through litigation. Many companies say it is hard-knock times like these that make protecting their intellectual property even more vital.

US Congress Hastens Through Flurry Of IP Legislation Before Departure

By Liza Porteus Viana for Intellectual Property Watch In the waning days of this congressional session in the United States, US lawmakers are passing a flurry of intellectual property-related bills. One of the bills awaiting President Bush’s signature would create…

Biotech, Pharma Industries To Target IP Protection Legislation, Patent Reform

By Liza Porteus Viana for Intellectual Property Watch
When the new administration and Congress come into office following the November elections in the United States, the pharmaceutical and biotechnology industries will prioritise protection of their intellectual property and innovative biological drugs as the push for cheaper, generic versions gets stronger. Patent reform also will continue to be a lobbying priority, as well as making sure intellectual property is protected in any forthcoming international trade agreements.

Industry Still Wary Of ICANN Plan For New Top-Level Internet Domains

By Liza Porteus Viana for Intellectual Property Watch The Internet Corporation for Assigned Names and Numbers (ICANN) has not adequately explained to the world the need for more generic top-level domains (gTLDs – such as .com), industry representatives said last…